ArticleFrontiers in pharmacology2025
Fangchinoline attenuates hepatic fibrosis by regulating taurine metabolism and oxidative stress.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fangchinoline (2021-2026): A Multitarget Bisbenzylisoquinoline Alkaloid With Emerging Anti-Infective Potential.Journal of tropical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic fibrosis emerges as a pathological hallmark in the pathogenesis of chronic hepatopathies. Methods: The DEN-induced hepatic fibrosis mouse model, primary murine hepatic stellate cells (HSCs), and TGF-β-induced activation model of HSCs were used to explore the anti-fibrotic effect of FAN. The proteomics analysis was used to predict the pharmacodynamic mechanisms of FAN, and follow-up validation assays were performed with Results: FAN alleviated DEN-induced liver fibrosis in mice, reducing biomarker levels, slowing histopathological changes, and inhibiting collagen deposition. FAN suppressed HSCs activation and the biosynthetic abilities of the extracellular matrix. Proteomics was used to explore the mechanisms of FAN action, which is related to the regulation of taurine metabolism. FAN reversed DEN-induced changes in the levels of taurine and key enzymes that catalyze taurine synthesis. Additional taurine reinforces the regulatory effect of FAN on HSCs activation. Taurine could inhibit oxidative stress. FAN reduced DEN-induced ROS accumulation, which may be associated with Nrf2 pathway activation. Cleaning ROS with N-acetylcysteine enhanced the anti-fibrotic effects of FAN. Conclusion: FAN can alleviate hepatic fibrosis by regulating taurine metabolism and oxidative stress, which has an important theoretical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.